NEW YORK and LONDON and MUNICH and NEW DELHI, Feb. 11, 2025 /PRNewswire/ -- Datar Cancer Genetics (DCG), a global leader…
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we,…
MUMBAI, India, Feb. 5, 2025 /PRNewswire/ -- On the occasion of World Cancer Day, the Centre for Environmental Research and Education…
The National Comprehensive Cancer Network joins a global day of advocacy to put people's individual needs and stories at the…
Cancer cases in India will see a 57.7% increase by 2040, unless a tailored policy is developed. NEW DELHI, Feb.…
LONDON, MUNICH and NEW DELHI, Feb. 3, 2025 /PRNewswire/ -- Datar Cancer Genetics (DCG) has launched Exacta AI, a next generation…
As seen in the DESTINY-Breast06 trial, approximately 20-25 percent of hormone receptor (HR)-positive, HER2-negative breast cancer patients may be considered…
NEW DELHI and LONDON and MUNICH, Jan. 28, 2025 /PRNewswire/ -- Datar Cancer Genetics (DCG) has launched a revolutionary video-reporting…
ATLANTA, Jan. 27, 2025 /PRNewswire/ -- Cambium Oncology is pleased to share that their lead drug candidate, ANT308, recently demonstrated…
The Target-MRD blood test uses a combination of tumor-informed and tumor-agnostic molecular features for personalized, accurate and more effective monitoring…
